Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Thalomid thalidomide: Phase II data; marketed to treat erythema nodosum leprosum in leprosy

Researchers presented additional data from a previously reported Phase II study showing a ?25 percent reduction

Read the full 167 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE